Download video

Glofitamab & Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma -Blood Cancers Video Library

105 views

Global Resource for Advancing Cancer Education

1 year ago

Glofitamab & Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma -Blood Cancers Video Library

Glofitamab & Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma -Blood Cancers Video Library

GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE
16:37
GLOFITAMAB PLUS POLATUZUMAB VEDOTIN DEMONSTRATES DURABLE RESPONSES AND A MANAGEABLE SAFETY PROFILE
by SSBMT جمعية الخلايا الجذعية
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
2:54
Updated results of glofitamab plus polatuzumab vedotin combination therapy in DLBCL, including HGBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R\/R DLBCL
2:04
The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R\/R DLBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
3:02
Efficacy of Epcoritamab and Glofitamab in Diffuse Large B-Cell Lymphoma
by Global Resource for Advancing Cancer Education
What Is Glofitamab
1:44
What Is Glofitamab
by RX Card Club
STARGLO 2-year follow-up: durability of responses in patients with DLBCL receiving Glofitamab-GemOx
1:29
STARGLO 2-year follow-up: durability of responses in patients with DLBCL receiving Glofitamab-GemOx
by VJHemOnc – Video Journal of Hematology \& HemOnc
Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023
4:22
Treatment Options of B-Cell Lymphoma: Glofitamab vs. Epcoritamab - Blood Cancer Video Library 2023
by Global Resource for Advancing Cancer Education
Glofitamab for Richter’s Transformation
6:53
Glofitamab for Richter’s Transformation
by CLL Society
Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL
1:49
Updates from the Phase II trials of glofitamab and epcoritamab for R\/R LBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
High Haematocrit due to SGLT2i: Lets Bleep Haematology😃
3:27
High Haematocrit due to SGLT2i: Lets Bleep Haematology😃
by Haematology, Morphology, FRCPath Exams
Pharmacology of Blinatumomab (Blincyto); Mechanism of action, Pharmacokinetics, Uses, Effects
2:28
Pharmacology of Blinatumomab (Blincyto); Mechanism of action, Pharmacokinetics, Uses, Effects
by MBBS NAIJA
Mantle Cell Lymphoma: Therapy for Relapsed Disease - 2025 Blood Cancer Video Library
6:23
Mantle Cell Lymphoma: Therapy for Relapsed Disease - 2025 Blood Cancer Video Library
by Global Resource for Advancing Cancer Education
Insights into Phase I\/II study assessing fixed-duration glofitamab treatment for R\/R LBCL
2:43
Insights into Phase I\/II study assessing fixed-duration glofitamab treatment for R\/R LBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Drs. Melody, Phillips discuss glofitamab trial, other MCL highlights at SOHO 2025
8:12
Drs. Melody, Phillips discuss glofitamab trial, other MCL highlights at SOHO 2025
by The Society of Hematologic Oncology
Michael Dickinson, MBBS, DMedSc, on Glofitamab Combination Trials Underway
3:36
Michael Dickinson, MBBS, DMedSc, on Glofitamab Combination Trials Underway
by Blood Cancers Today
Glofitamab in R\/R DLBCL: updated safety and efficacy data
5:30
Glofitamab in R\/R DLBCL: updated safety and efficacy data
by VJHemOnc – Video Journal of Hematology \& HemOnc
ASH highlights: glofitamab in DLBCL \& pirtobrutinib and epcoritamab in Richter's transformation
1:58
ASH highlights: glofitamab in DLBCL \& pirtobrutinib and epcoritamab in Richter's transformation
by VJHemOnc – Video Journal of Hematology \& HemOnc
Glofitamab as a single agent in heavily pretreated patients with DLBCL
2:33
Glofitamab as a single agent in heavily pretreated patients with DLBCL
by VJHemOnc – Video Journal of Hematology \& HemOnc
NP30179: Glofitamab monotherapy in R\/R NHL
0:50
NP30179: Glofitamab monotherapy in R\/R NHL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \& glofitamab
1:31
Advantages of bispecific antibodies for lymphoma: mosunetuzumab, epcoritamab \& glofitamab
by VJHemOnc – Video Journal of Hematology \& HemOnc
Glofitamab for Relapsed\/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24
3:26
Glofitamab for Relapsed\/Refractory Large B-cell Lymphomas | Joshua Brody, MD | #ASH24
by HealthTree Foundation for Blood Cancers
A Phase I study of glofitamab plus a novel CD19 x CD28 costimulatory agonist in R\/R B-NHL
3:56
A Phase I study of glofitamab plus a novel CD19 x CD28 costimulatory agonist in R\/R B-NHL
by VJHemOnc – Video Journal of Hematology \& HemOnc
Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy
1:22
Glofitamab as a SOC in third-line DLBCL and its potential in earlier lines of therapy
by VJHemOnc – Video Journal of Hematology \& HemOnc